Brief: Paxmedica Submits Clinical Trial Request In Autism Spectrum Disorder
14/06/2023 14:42
PaxMedica Inc PXMD.O :
* PAXMEDICA SUBMITS CLINICAL TRIAL REQUEST IN AUTISM
SPECTRUM
DISORDER
* PAXMEDICA INC - PAX-101 INTERNALLY DEVELOPED SUPPLY CHAIN
ENTERING FINAL STAGES
* PAXMEDICA INC - ASD-101 PROTOCOL SUBMITTED TO SAHPRA,
SOUTH
AFRICA'S REGULATORY AGENCY
Source text for Eikon: ID:nGNX4vW3pj
Further company coverage: PXMD.O
Recent news on Kuvatris Therapeutics
See all newsBrief: PaxMedica Responds To Emergency Request For IV Suramin And Commits To Provide Immediate Access To PAX-101
PaxMedica rises on Malawi's request for access to sleeping sickness drug
Brief: Paxmedica Receives Emergency Request For Iv Suramin From African Health Ministry For Use In Treating Fatal Sleeping Sickness
Brief: PaxMedica Achieves Key Milestone In The Development Of PAX-101 And Provides Update On Potential NDA Submission
Brief: Paxmedica Announces Pricing Of $7.0 Million Public Offering